Search clinical trials for: Chimeric Antigen Receptor (CAR) T cells

Total 497408 results

Bioray Laboratories
First Affiliated Hospital of Zhejiang University

Completed

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

B-cell Lymphoma

China
Zhejiang University
Bioray Laboratories

Completed

PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer

Castrate-Resistant Prostate Cancer

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Sheba Medical Center

Recruiting

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Acute Myeloid Leukemia

Israel
University College, London

Active, not recruiting

A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY)

Multiple Myeloma

United Kingdom
Chimeric Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors

United States
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
Southwest Hospital, China

Recruiting

A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Lymphoma | Leukemia

China
Northwestern University
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
CAR-T (Shanghai) Biotechnology Co., Ltd.

Not yet recruiting

Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression

Depression
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells

COVID-19
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

Knee Osteoarthritis

China
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function

Type1diabetes

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Esophageal Cancer | Lung Cancer | Rectal Cancer | Colon Cancer | Pancreas Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Acute Myeloid Leukemia | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Extranodal NK/T-cell Lymphoma, Nasal Type | T-cell Prolymphocytic Leukemia | T-cell Large Granular Lymphocytic Leukemia | Peripheral T-cell Lymphoma, NOS | Enteropathy-type Intestinal T-cell Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Dipenkumar Modi
Genmab

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Relapsed Cancer | Refractory Cancer | Large Cell Lymphoma, Diffuse

United States
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (BERING-CRC)

Metastatic Colorectal Carcinoma

Austria, Germany
Chinese PLA General Hospital

Unknown

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Vor Biopharma

Recruiting

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute

United States
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma
Jazz Pharmaceuticals

Terminated

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

Neurotoxicity Syndromes | DLBCL

United States
Chembrain LTD
University of Oulu; Jyväskylä Central Hospital; Apollo Hospital, New Delhi, India

Active, not recruiting

The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients (CARTREMENDOUS)

Glioblastoma | Glioblastoma Multiforme | Glioma, Malignant

Finland, India
Zhejiang University
CARsgen Therapeutics Co., Ltd.

Completed

4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3

Advanced Hepatocellular Carcinoma

China
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET)

Acute Lymphoblastic Leukemia

United States
Baylor College of Medicine
Cancer Prevention Research Institute of Texas; Center for Cell and Gene Therapy... and other collaborators

Active, not recruiting

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)

Liver Cancer

United States
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

PSMA-specific CAR-T Cell Therapy

PSMA Positive Tumors or Tumor Tissues

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Recurrent Mantle Cell Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Refractory Chronic Lymphocytic Leukemia | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Acute Lymphoblastic Leukemia | Metastatic Triple-Negative... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Hepatocellular Carcinoma | Hepatoblastoma
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Acute Lymphoblastic Leukemia With Failed Remission

China
Han weidong

Recruiting

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | Decitabine-primed Tandem CD19/CD20 CAR T Cells

China
Second Affiliated Hospital of Soochow University
Soochow T-Maximun Biotechnology Co. LTD

Recruiting

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma

Advanced Glioma | Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy

China
Memorial Sloan Kettering Cancer Center
United States Department of Defense

Active, not recruiting

T-Cell Therapy for Advanced Breast Cancer

Breast Cancer | Metastatic HER2-negative Breast

United States
Chongqing Precision Biotech Co., Ltd
Zhejiang University

Recruiting

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Breast Cancer | Gastric Cancer | Colorectal Cancer | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Esophagus Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Hepatocellular Carcinoma | Malignant Glioma of Brain | Non-small Cell Lung Cancer | Gastric Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
C. Babis Andreadis
University of California, Davis

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

United States
Beijing 302 Hospital
Tsinghua University

Unknown

Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection (TCTIWHI)

HIV-1

China
Novartis Pharmaceuticals
University of Pennsylvania

Recruiting

CAR-T Long Term Follow Up (LTFU) Study (PAVO)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

United States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Chunrui Li
Nanjing IASO Biotechnology Co., Ltd

Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Leukemia | Relapsed/Refractory Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Terminated

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Safety and Efficacy

China
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Terminated

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
Rhode Island Hospital

Withdrawn

Evaluating Models for Dissemination of Injury Prevention Information in the Pediatric Emergency Department Setting

Injuries | Car Seats

United States
Chongqing Precision Biotech Co., Ltd
First Affiliated Hospital of Wannan Medical College

Recruiting

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Breast Cancer | Gastric Cancer | Lung Cancer | Rectal Cancer | Cholangiocarcinoma | Colon Cancer | Pancreas Cancer | Esophagus Cancer

China

Search clinical trials for: Chimeric Antigen Receptor (CAR) T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations